MA41758A - Procédés de traitement de l'infertilité - Google Patents
Procédés de traitement de l'infertilitéInfo
- Publication number
- MA41758A MA41758A MA041758A MA41758A MA41758A MA 41758 A MA41758 A MA 41758A MA 041758 A MA041758 A MA 041758A MA 41758 A MA41758 A MA 41758A MA 41758 A MA41758 A MA 41758A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- infertility treatment
- ovarian stimulation
- controlled ovarian
- controlled
- Prior art date
Links
- 208000000509 infertility Diseases 0.000 title 1
- 230000036512 infertility Effects 0.000 title 1
- 231100000535 infertility Toxicity 0.000 title 1
- 230000002611 ovarian Effects 0.000 abstract 3
- 230000000638 stimulation Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
Abstract
La présente invention concerne une technologie de reproduction assistée améliorée utilisant de la ménotropine hautement purifiée (hp-hmg) pour stimuler le développement de follicules dans une stimulation ovarienne contrôlée, en particulier chez des femmes présentant un risque élevé de réponse ovarienne à une stimulation ovarienne contrôlée.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562121113P | 2015-02-26 | 2015-02-26 | |
US201562121131P | 2015-02-26 | 2015-02-26 | |
EP15157661 | 2015-03-04 | ||
EP15185191 | 2015-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41758A true MA41758A (fr) | 2018-01-03 |
MA41758B1 MA41758B1 (fr) | 2024-03-29 |
Family
ID=56787937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41758A MA41758B1 (fr) | 2015-02-26 | 2016-02-25 | Procédés de traitement de l'infertilité |
Country Status (25)
Country | Link |
---|---|
US (4) | US10413592B2 (fr) |
EP (2) | EP4289477A3 (fr) |
JP (2) | JP7163027B2 (fr) |
KR (1) | KR102618298B1 (fr) |
CN (2) | CN113769069A (fr) |
AU (1) | AU2016223496B2 (fr) |
CA (1) | CA2976032A1 (fr) |
DK (1) | DK3261661T3 (fr) |
ES (1) | ES2968102T3 (fr) |
FI (1) | FI3261661T3 (fr) |
HK (1) | HK1246655A1 (fr) |
HR (1) | HRP20240013T1 (fr) |
HU (1) | HUE064604T2 (fr) |
LT (1) | LT3261661T (fr) |
MA (1) | MA41758B1 (fr) |
MD (1) | MD3261661T2 (fr) |
MX (1) | MX2017010320A (fr) |
PH (1) | PH12017501493A1 (fr) |
PL (1) | PL3261661T3 (fr) |
RS (1) | RS65096B1 (fr) |
RU (1) | RU2723098C2 (fr) |
SG (1) | SG11201706693QA (fr) |
SI (1) | SI3261661T1 (fr) |
WO (1) | WO2016135221A1 (fr) |
ZA (1) | ZA201705489B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3261661T3 (pl) | 2015-02-26 | 2024-03-25 | Ferring B.V. | Menotropina do leczenia niepłodności |
IL272763B2 (en) | 2017-09-01 | 2024-02-01 | Ferring Bv | The composition for controlled stimulation of the ovary |
CN109602394B (zh) * | 2018-12-12 | 2020-01-17 | 北京大学第三医院 | 评估受试者卵巢储备功能的*** |
CN110491505B (zh) * | 2019-08-22 | 2021-06-01 | 北京大学第三医院(北京大学第三临床医学院) | 预测受试者卵巢刺激过程中获得的***数量的*** |
EP3932419A1 (fr) * | 2020-06-29 | 2022-01-05 | Ferring B.V. | Procédés de traitement de la stérilité |
TW202210096A (zh) * | 2020-05-29 | 2022-03-16 | 荷蘭商菲林公司 | 治療不育症之方法 |
EP4171612A1 (fr) * | 2020-06-26 | 2023-05-03 | Ferring B.V. | Hp-hmg pour une utilisation dans le traitement de l'infertilité chez une patiente atteint d'un syndrome des ovaires polykystiques |
KR102498267B1 (ko) | 2021-01-13 | 2023-02-13 | 주식회사 아이웍스 | 마이크로버블 생성 혼합 수중 에어레이터 회전분사 조립체 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725579A (en) | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
EP1169349B1 (fr) | 1999-04-16 | 2007-03-28 | Instituto Massone S.A. | Procede de preparation des compositions de gonadotrophines |
WO2003022303A2 (fr) | 2001-09-12 | 2003-03-20 | Applied Research Systems Ars Holding N.V. | Utilisation de hcg et de lh in dans l'hyperstimulation ovarienne controlee |
US20140235540A1 (en) | 2008-05-20 | 2014-08-21 | Norbert Gleicher | Androgen and gonadotropin treatment in females |
RU2466724C1 (ru) | 2011-05-31 | 2012-11-20 | Фатима Якубовна Богатырева | Способ лечения больных бесплодием, обусловленным поликистозом яичников, яичникового генеза на фоне хронического и острого воспаления органов малого таза |
US9404908B2 (en) * | 2013-04-29 | 2016-08-02 | The Board of Truestees of the Leland Stanford Junior University | Non-invasive imaging to the blastocyst stage for the detection of human embryonic aneuploidy |
PL3261661T3 (pl) | 2015-02-26 | 2024-03-25 | Ferring B.V. | Menotropina do leczenia niepłodności |
-
2016
- 2016-02-25 PL PL16709720.3T patent/PL3261661T3/pl unknown
- 2016-02-25 MD MDE20180026T patent/MD3261661T2/ro unknown
- 2016-02-25 RU RU2017131129A patent/RU2723098C2/ru active
- 2016-02-25 EP EP23195379.5A patent/EP4289477A3/fr active Pending
- 2016-02-25 CA CA2976032A patent/CA2976032A1/fr active Pending
- 2016-02-25 FI FIEP16709720.3T patent/FI3261661T3/fi active
- 2016-02-25 JP JP2017545238A patent/JP7163027B2/ja active Active
- 2016-02-25 LT LTEPPCT/EP2016/053934T patent/LT3261661T/lt unknown
- 2016-02-25 HR HRP20240013TT patent/HRP20240013T1/hr unknown
- 2016-02-25 EP EP16709720.3A patent/EP3261661B1/fr active Active
- 2016-02-25 MX MX2017010320A patent/MX2017010320A/es unknown
- 2016-02-25 RS RS20240071A patent/RS65096B1/sr unknown
- 2016-02-25 CN CN202111138328.6A patent/CN113769069A/zh active Pending
- 2016-02-25 DK DK16709720.3T patent/DK3261661T3/da active
- 2016-02-25 HU HUE16709720A patent/HUE064604T2/hu unknown
- 2016-02-25 ES ES16709720T patent/ES2968102T3/es active Active
- 2016-02-25 CN CN201680011732.8A patent/CN107257690A/zh active Pending
- 2016-02-25 WO PCT/EP2016/053934 patent/WO2016135221A1/fr active Application Filing
- 2016-02-25 KR KR1020177026095A patent/KR102618298B1/ko active IP Right Grant
- 2016-02-25 SG SG11201706693QA patent/SG11201706693QA/en unknown
- 2016-02-25 MA MA41758A patent/MA41758B1/fr unknown
- 2016-02-25 SI SI201631789T patent/SI3261661T1/sl unknown
- 2016-02-25 AU AU2016223496A patent/AU2016223496B2/en active Active
- 2016-02-25 US US15/053,116 patent/US10413592B2/en active Active
-
2017
- 2017-08-14 ZA ZA2017/05489A patent/ZA201705489B/en unknown
- 2017-08-17 PH PH12017501493A patent/PH12017501493A1/en unknown
-
2018
- 2018-05-11 HK HK18106172.7A patent/HK1246655A1/zh unknown
-
2019
- 2019-08-29 US US16/555,688 patent/US11351228B2/en active Active
-
2020
- 2020-08-20 JP JP2020139478A patent/JP7157108B2/ja active Active
- 2020-12-10 US US17/117,643 patent/US11679145B2/en active Active
-
2023
- 2023-05-05 US US18/144,046 patent/US20240009278A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41758A (fr) | Procédés de traitement de l'infertilité | |
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
WO2016100261A3 (fr) | Procédé de traitement du cancer avec cgamp ou cgasmp | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2021015783A (es) | Metodos de tratamiento de enfermedades colestaticas. | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA46548A (fr) | Fsh pour le traitement de l'infertilité | |
EA201791845A1 (ru) | Твердые формы менахинолов | |
EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
WO2016042561A3 (fr) | Freination du mir-132 pour le traitement de troubles lipidiques | |
MY202466A (en) | Methods for treatment of polycystic kidney disease | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
MA50163A (fr) | Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité | |
EA201890514A1 (ru) | Соединение тетрагидрооксепинопиридина | |
MA41930A1 (fr) | Composition pour traitement de la maladie du bayoud | |
EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств | |
MA38411B1 (fr) | Inhibiteurs de cdc7 | |
UA95472U (uk) | Спосіб лікування хворих на неалкогольну жирову хворобу печінки |